New scan could reveal hidden aggression in brain tumors

NCT ID NCT06059690

Recruiting now Knowledge-focused Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new combined MRI and PET scan that measures how active brain tumor cells are by looking at their energy use (glycolysis). Researchers will take small tissue samples during surgery to check if the scan matches the tumor's actual biology. The goal is to better identify the most dangerous parts of glioblastoma tumors, which could help guide future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better imaging tools to see how aggressive a brain tumor is and help surgeons target the most dangerous parts during surgery.
What could go wrong: This is an early-phase study with only 50 participants, focused on validating a new imaging method, not on treatment. The technique may not prove accurate or useful in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPIDERMAL GROWTH FACTOR RECEPTOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPIDERMAL GROWTH FACTOR RECEPTOR GLIOBLASTOMA MULTIFORME GLYCOLYTIC INDEX

Contacts and locations

Locations

University of California at Los Angeles
RECRUITING

Los Angeles, California, 90095-1406, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.